Report overview
This report contains market size and forecasts of Non-muscle Invasive Bladder Cancer Therapeutics in Global, including the following market information:
Global Non-muscle Invasive Bladder Cancer Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Non-muscle Invasive Bladder Cancer Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Intravesical Chemotherapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Non-muscle Invasive Bladder Cancer Therapeutics include F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca, Pfizer Inc., GlaxoSmithKline plc., Sanofi S.A., Novartis AG, Eli Lilly and Company and Merck & Co., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Non-muscle Invasive Bladder Cancer Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-muscle Invasive Bladder Cancer Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Non-muscle Invasive Bladder Cancer Therapeutics Market Segment Percentages, by Type, 2021 (%)
Intravesical Chemotherapy
Intravesical Immunotherapy
Global Non-muscle Invasive Bladder Cancer Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Non-muscle Invasive Bladder Cancer Therapeutics Market Segment Percentages, by Application, 2021 (%)
Hospital
Ambulatory Surgery Center
Others
Global Non-muscle Invasive Bladder Cancer Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Non-muscle Invasive Bladder Cancer Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-muscle Invasive Bladder Cancer Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Non-muscle Invasive Bladder Cancer Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
AstraZeneca
Pfizer Inc.
GlaxoSmithKline plc.
Sanofi S.A.
Novartis AG
Eli Lilly and Company
Merck & Co.
Viventia Bio Inc.
Celgene Corporation
Spectrum Pharmaceuticals, Inc.
Herantis Pharma Plc.
Taris Biomedical LLC
Prometic Life Sciences Inc.
Telormediz S.A.
Heat Biologics
Altor BioScience
Ferring B.V.
Cold Genesys Inc.
